Share Price and Basic Stock Data
Last Updated: December 19, 2025, 5:27 pm
| PEG Ratio | -12.60 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Thyrocare Technologies Ltd operates in the rapidly evolving Hospitals and Medical Services sector, primarily focusing on diagnostic services. As of the latest reports, the company achieved sales of ₹524 Cr for the fiscal year ending March 2024, which represents a modest increase from ₹486 Cr in the previous year. This growth trajectory is noteworthy, especially considering the fluctuations observed in its quarterly sales, which ranged from ₹117 Cr in December 2022 to ₹141 Cr in March 2024. The most recent quarter, June 2025, recorded sales of ₹179 Cr, highlighting an upward trend that suggests improving demand for its services. However, the overall sales growth has not been linear, indicating potential challenges in maintaining consistent revenue streams. The company’s ability to adapt and innovate will be crucial in sustaining its growth amidst competitive pressures in the healthcare sector.
Profitability and Efficiency Metrics
Thyrocare’s profitability metrics present a mixed picture. The company reported a net profit of ₹71 Cr for FY 2025, showing a recovery from the ₹57 Cr reported in FY 2023. Operating profit margins (OPM) have fluctuated but stood at 30% for FY 2025, reflecting a notable improvement from 24% in FY 2023. However, this is still below the historical peak of 46% recorded in FY 2014. The return on equity (ROE) remains commendable at 16.73%, which indicates effective management of shareholder funds despite recent dips in profitability. On the efficiency front, the cash conversion cycle turned negative to -9 days in FY 2025, showcasing improved operational efficiency by converting sales into cash more quickly. Nonetheless, high levels of debt and fluctuating margins point to underlying risks that investors should watch closely.
Balance Sheet Strength and Financial Ratios
Thyrocare’s balance sheet appears robust, with total assets standing at ₹676 Cr against relatively low borrowings of ₹23 Cr, reflecting a strong equity base and minimal leverage. The current ratio of 2.77 indicates that the company is well-positioned to cover its short-term liabilities. Additionally, the interest coverage ratio (ICR) of 67.28x further underscores its ability to meet interest obligations comfortably, which is a positive sign for risk-averse investors. However, the price-to-book value (P/BV) ratio of 6.59x suggests that the stock may be trading at a premium, raising concerns about valuation. While the reserves have remained stable at around ₹484 Cr, the declining trend in cash earnings retention ratios indicates a potential challenge in funding future growth or dividends without external financing.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Thyrocare reflects a strong promoter commitment, with promoters holding 71.06% of the equity shares. This level of control can be reassuring for retail investors, as it suggests a long-term vision for the company. However, foreign institutional investments (FIIs) have seen a significant decline, falling from about 10% in December 2022 to 4.85% by March 2025, which might raise concerns regarding international investor confidence in the company’s prospects. Domestic institutional investors (DIIs) have maintained a stable presence at around 13.47%, contributing to a balanced ownership structure. The decline in the number of shareholders from 75,822 in December 2022 to 54,142 in September 2025 might indicate a lack of retail interest or confidence, which is an area for management to address to bolster broader investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Thyrocare’s prospects are intertwined with both opportunities and risks. On one hand, the increasing demand for diagnostic services in India, driven by a growing healthcare awareness, presents a favorable environment for revenue growth. On the other hand, the company faces challenges such as fluctuating margins and potential competition from both established players and new entrants in the market. The high P/BV ratio raises questions about whether the stock is overvalued, especially in light of recent profitability fluctuations. Investors may want to consider these aspects carefully; while the underlying business fundamentals remain strong, the stock’s current valuation could lead to volatility. Ultimately, Thyrocare’s ability to innovate and navigate market dynamics will be pivotal in determining its long-term success and investor returns.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 41.6 Cr. | 124 | 194/120 | 8.48 | 117 | 2.82 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.5 Cr. | 20.5 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 8.57 Cr. | 8.29 | 20.8/7.86 | 95.2 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 113 Cr. | 60.4 | 98.7/55.2 | 25.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.0 Cr. | 3.71 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,148.29 Cr | 688.57 | 94.60 | 93.18 | 0.35% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 119 | 125 | 117 | 125 | 124 | 136 | 123 | 141 | 144 | 163 | 153 | 174 | 179 |
| Expenses | 85 | 96 | 91 | 102 | 90 | 100 | 92 | 108 | 101 | 114 | 112 | 118 | 122 |
| Operating Profit | 34 | 30 | 26 | 23 | 33 | 37 | 31 | 34 | 42 | 49 | 40 | 56 | 57 |
| OPM % | 28% | 24% | 22% | 18% | 27% | 27% | 25% | 24% | 29% | 30% | 26% | 32% | 32% |
| Other Income | 1 | 1 | 1 | 2 | 0 | 2 | 2 | 3 | 3 | 2 | 4 | 5 | 4 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 8 | 8 | 9 | 9 | 9 | 9 | 11 | 10 | 9 | 10 | 15 | 12 | 9 |
| Profit before tax | 27 | 22 | 18 | 15 | 24 | 28 | 21 | 25 | 35 | 40 | 28 | 48 | 51 |
| Tax % | 24% | 35% | 28% | 33% | 31% | 28% | 28% | 23% | 28% | 27% | 32% | 54% | 29% |
| Net Profit | 20 | 14 | 13 | 10 | 17 | 20 | 15 | 19 | 25 | 30 | 19 | 22 | 36 |
| EPS in Rs | 3.80 | 2.70 | 2.39 | 1.88 | 3.16 | 3.83 | 2.81 | 3.63 | 4.75 | 5.59 | 3.60 | 4.14 | 6.80 |
Last Updated: August 1, 2025, 10:15 am
Below is a detailed analysis of the quarterly data for Thyrocare Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 179.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2025) to 179.00 Cr., marking an increase of 5.00 Cr..
- For Expenses, as of Jun 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 118.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 4.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 56.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 32.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 32.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 48.00 Cr. (Mar 2025) to 51.00 Cr., marking an increase of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 29.00%. The value appears to be improving (decreasing) as expected. It has decreased from 54.00% (Mar 2025) to 29.00%, marking a decrease of 25.00%.
- For Net Profit, as of Jun 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.80. The value appears strong and on an upward trend. It has increased from 4.14 (Mar 2025) to 6.80, marking an increase of 2.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:30 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 150 | 180 | 235 | 298 | 332 | 370 | 401 | 474 | 562 | 486 | 524 | 633 | 708 |
| Expenses | 81 | 109 | 140 | 182 | 193 | 222 | 233 | 304 | 330 | 371 | 388 | 446 | 486 |
| Operating Profit | 69 | 71 | 95 | 115 | 139 | 148 | 168 | 171 | 232 | 115 | 136 | 188 | 221 |
| OPM % | 46% | 40% | 40% | 39% | 42% | 40% | 42% | 36% | 41% | 24% | 26% | 30% | 31% |
| Other Income | 7 | 13 | 6 | -16 | 21 | 14 | -35 | 12 | 7 | 5 | 6 | 13 | 14 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 5 | 3 | 2 |
| Depreciation | 6 | 11 | 11 | 12 | 12 | 14 | 20 | 21 | 28 | 34 | 39 | 47 | 46 |
| Profit before tax | 69 | 73 | 89 | 87 | 148 | 147 | 112 | 161 | 207 | 81 | 98 | 151 | 188 |
| Tax % | 33% | 33% | 34% | 46% | 35% | 35% | 29% | 26% | 27% | 30% | 28% | 37% | |
| Net Profit | 46 | 49 | 59 | 47 | 96 | 95 | 79 | 120 | 152 | 57 | 71 | 96 | 120 |
| EPS in Rs | 14.07 | 3.25 | 3.64 | 2.90 | 5.96 | 6.01 | 5.00 | 7.55 | 9.58 | 3.59 | 4.48 | 6.02 | 7.56 |
| Dividend Payout % | 0% | 157% | 91% | 115% | 56% | 111% | 33% | 110% | 52% | 167% | 134% | 116% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.52% | 20.41% | -20.34% | 104.26% | -1.04% | -16.84% | 51.90% | 26.67% | -62.50% | 24.56% | 35.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | 13.89% | -40.75% | 124.59% | -105.30% | -15.80% | 68.74% | -25.23% | -89.17% | 87.06% | 10.65% |
Thyrocare Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 4% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -3% |
| 3 Years: | -15% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 27% |
| 1 Year: | 55% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 19% |
| 3 Years: | 14% |
| Last Year: | 17% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: December 10, 2025, 3:33 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 195 | 229 | 322 | 364 | 400 | 403 | 325 | 393 | 468 | 468 | 461 | 484 | 463 |
| Borrowings | 25 | -0 | -0 | -0 | -0 | -0 | 9 | 10 | 21 | 21 | 39 | 23 | 22 |
| Other Liabilities | 14 | 14 | 39 | 26 | 31 | 32 | 55 | 73 | 55 | 70 | 68 | 116 | 113 |
| Total Liabilities | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 676 | 651 |
| Fixed Assets | 87 | 83 | 93 | 89 | 103 | 108 | 112 | 119 | 149 | 157 | 159 | 158 | 160 |
| CWIP | 6 | 6 | 1 | 2 | -0 | 1 | 4 | 8 | 2 | 1 | 1 | 14 | 3 |
| Investments | 119 | 162 | 266 | 299 | 315 | 289 | 239 | 274 | 259 | 274 | 291 | 284 | 265 |
| Other Assets | 33 | 42 | 55 | 54 | 68 | 89 | 88 | 127 | 186 | 180 | 169 | 221 | 223 |
| Total Assets | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 676 | 651 |
Below is a detailed analysis of the balance sheet data for Thyrocare Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 53.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 53.00 Cr..
- For Reserves, as of Sep 2025, the value is 463.00 Cr.. The value appears to be declining and may need further review. It has decreased from 484.00 Cr. (Mar 2025) to 463.00 Cr., marking a decrease of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 23.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 113.00 Cr.. The value appears to be improving (decreasing). It has decreased from 116.00 Cr. (Mar 2025) to 113.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 651.00 Cr.. The value appears to be improving (decreasing). It has decreased from 676.00 Cr. (Mar 2025) to 651.00 Cr., marking a decrease of 25.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 158.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 265.00 Cr.. The value appears to be declining and may need further review. It has decreased from 284.00 Cr. (Mar 2025) to 265.00 Cr., marking a decrease of 19.00 Cr..
- For Other Assets, as of Sep 2025, the value is 223.00 Cr.. The value appears strong and on an upward trend. It has increased from 221.00 Cr. (Mar 2025) to 223.00 Cr., marking an increase of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 651.00 Cr.. The value appears to be declining and may need further review. It has decreased from 676.00 Cr. (Mar 2025) to 651.00 Cr., marking a decrease of 25.00 Cr..
Notably, the Reserves (463.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 44.00 | 71.00 | 95.00 | 115.00 | 139.00 | 148.00 | 159.00 | 161.00 | 211.00 | 94.00 | 97.00 | 165.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12 | 9 | 11 | 7 | 10 | 11 | 14 | 34 | 60 | 63 | 28 | 40 |
| Inventory Days | 54 | 47 | 54 | 64 | 66 | 54 | 60 | 50 | 54 | 63 | 106 | 93 |
| Days Payable | 13 | 5 | 8 | 4 | 23 | 19 | 62 | 48 | 30 | 52 | 83 | 141 |
| Cash Conversion Cycle | 53 | 51 | 57 | 68 | 53 | 46 | 12 | 37 | 84 | 74 | 51 | -9 |
| Working Capital Days | 22 | 52 | 15 | 28 | 11 | 4 | -12 | 7 | 45 | 34 | 14 | 18 |
| ROCE % | 33% | 27% | 27% | 29% | 33% | 31% | 36% | 37% | 41% | 15% | 18% | 26% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 5,167,803 | 0.37 | 256.17 | 1,722,601 | 2025-12-15 03:04:08 | 200% |
| Nippon India Pharma Fund | 4,392,120 | 2.57 | 217.72 | 1,548,692 | 2025-12-14 07:13:13 | 183.6% |
| HSBC Midcap Fund | 4,373,100 | 1.73 | 216.77 | 950,000 | 2025-12-14 07:13:13 | 360.33% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 2,873,886 | 0.91 | 142.46 | 1,033,015 | 2025-12-14 07:13:13 | 178.2% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 2,804,472 | 2.15 | 139.02 | 934,824 | 2025-12-14 07:13:13 | 200% |
| ICICI Prudential Dividend Yield Equity Fund | 1,909,800 | 1.49 | 94.67 | 636,600 | 2025-12-14 04:15:52 | 200% |
| HSBC Large & Mid Cap Fund | 1,737,570 | 1.85 | 86.13 | 434,594 | 2025-12-15 01:20:14 | 299.81% |
| ICICI Prudential Multicap Fund | 1,311,450 | 0.4 | 65.01 | 437,150 | 2025-12-14 07:13:13 | 200% |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 354,579 | 2.06 | 17.58 | N/A | N/A | N/A |
| Aditya Birla Sun Life Bal Bhavishya Yojna | 280,398 | 1.16 | 13.9 | 147,495 | 2025-12-14 07:13:13 | 90.11% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 17.13 | 13.42 | 12.16 | 33.30 | 21.41 |
| Diluted EPS (Rs.) | 17.08 | 13.40 | 12.14 | 33.25 | 21.37 |
| Cash EPS (Rs.) | 27.83 | 21.93 | 19.25 | 39.73 | 27.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 103.18 | 99.65 | 101.12 | 99.54 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 103.18 | 99.65 | 101.12 | 99.54 | 80.81 |
| Revenue From Operations / Share (Rs.) | 129.71 | 108.00 | 99.50 | 111.32 | 93.55 |
| PBDIT / Share (Rs.) | 38.72 | 27.72 | 24.27 | 49.93 | 34.74 |
| PBIT / Share (Rs.) | 28.29 | 18.85 | 16.96 | 43.53 | 29.02 |
| PBT / Share (Rs.) | 27.72 | 18.05 | 16.51 | 43.08 | 28.85 |
| Net Profit / Share (Rs.) | 17.40 | 13.05 | 11.94 | 33.33 | 21.41 |
| NP After MI And SOA / Share (Rs.) | 17.27 | 13.36 | 12.16 | 33.30 | 21.40 |
| PBDIT Margin (%) | 29.85 | 25.66 | 24.39 | 44.85 | 37.13 |
| PBIT Margin (%) | 21.81 | 17.44 | 17.04 | 39.10 | 31.01 |
| PBT Margin (%) | 21.36 | 16.71 | 16.59 | 38.70 | 30.83 |
| Net Profit Margin (%) | 13.41 | 12.08 | 11.99 | 29.94 | 22.89 |
| NP After MI And SOA Margin (%) | 13.31 | 12.37 | 12.22 | 29.91 | 22.87 |
| Return on Networth / Equity (%) | 16.73 | 13.43 | 12.04 | 33.45 | 26.48 |
| Return on Capital Employeed (%) | 26.26 | 18.03 | 16.15 | 42.39 | 34.03 |
| Return On Assets (%) | 13.20 | 10.98 | 10.17 | 28.98 | 20.73 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 1.03 | 0.89 | 0.79 | 0.98 | 0.94 |
| Current Ratio (X) | 2.77 | 3.08 | 3.54 | 4.18 | 2.50 |
| Quick Ratio (X) | 2.39 | 2.55 | 3.18 | 3.80 | 2.26 |
| Inventory Turnover Ratio (X) | 14.62 | 4.38 | 5.82 | 6.80 | 7.44 |
| Dividend Payout Ratio (NP) (%) | 104.15 | 134.63 | 123.29 | 45.02 | 46.69 |
| Dividend Payout Ratio (CP) (%) | 64.93 | 80.89 | 76.98 | 37.76 | 36.84 |
| Earning Retention Ratio (%) | -4.15 | -34.63 | -23.29 | 54.98 | 53.31 |
| Cash Earning Retention Ratio (%) | 35.07 | 19.11 | 23.02 | 62.24 | 63.16 |
| Interest Coverage Ratio (X) | 67.28 | 34.95 | 54.67 | 111.45 | 211.14 |
| Interest Coverage Ratio (Post Tax) (X) | 31.23 | 17.45 | 27.89 | 75.40 | 131.14 |
| Enterprise Value (Cr.) | 3550.20 | 3118.27 | 2246.85 | 4079.23 | 4758.17 |
| EV / Net Operating Revenue (X) | 5.17 | 5.45 | 4.27 | 6.93 | 9.62 |
| EV / EBITDA (X) | 17.30 | 21.24 | 17.49 | 15.44 | 25.90 |
| MarketCap / Net Operating Revenue (X) | 5.24 | 5.48 | 4.32 | 6.95 | 9.65 |
| Retention Ratios (%) | -4.15 | -34.63 | -23.29 | 54.97 | 53.30 |
| Price / BV (X) | 6.59 | 5.95 | 4.26 | 7.77 | 11.17 |
| Price / Net Operating Revenue (X) | 5.24 | 5.48 | 4.32 | 6.95 | 9.65 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 |
After reviewing the key financial ratios for Thyrocare Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.13. This value is within the healthy range. It has increased from 13.42 (Mar 24) to 17.13, marking an increase of 3.71.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.08. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 17.08, marking an increase of 3.68.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.83. This value is within the healthy range. It has increased from 21.93 (Mar 24) to 27.83, marking an increase of 5.90.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.18. It has increased from 99.65 (Mar 24) to 103.18, marking an increase of 3.53.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.18. It has increased from 99.65 (Mar 24) to 103.18, marking an increase of 3.53.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 129.71. It has increased from 108.00 (Mar 24) to 129.71, marking an increase of 21.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 38.72. This value is within the healthy range. It has increased from 27.72 (Mar 24) to 38.72, marking an increase of 11.00.
- For PBIT / Share (Rs.), as of Mar 25, the value is 28.29. This value is within the healthy range. It has increased from 18.85 (Mar 24) to 28.29, marking an increase of 9.44.
- For PBT / Share (Rs.), as of Mar 25, the value is 27.72. This value is within the healthy range. It has increased from 18.05 (Mar 24) to 27.72, marking an increase of 9.67.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.40. This value is within the healthy range. It has increased from 13.05 (Mar 24) to 17.40, marking an increase of 4.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.27. This value is within the healthy range. It has increased from 13.36 (Mar 24) to 17.27, marking an increase of 3.91.
- For PBDIT Margin (%), as of Mar 25, the value is 29.85. This value is within the healthy range. It has increased from 25.66 (Mar 24) to 29.85, marking an increase of 4.19.
- For PBIT Margin (%), as of Mar 25, the value is 21.81. This value exceeds the healthy maximum of 20. It has increased from 17.44 (Mar 24) to 21.81, marking an increase of 4.37.
- For PBT Margin (%), as of Mar 25, the value is 21.36. This value is within the healthy range. It has increased from 16.71 (Mar 24) to 21.36, marking an increase of 4.65.
- For Net Profit Margin (%), as of Mar 25, the value is 13.41. This value exceeds the healthy maximum of 10. It has increased from 12.08 (Mar 24) to 13.41, marking an increase of 1.33.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 12.37 (Mar 24) to 13.31, marking an increase of 0.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.73. This value is within the healthy range. It has increased from 13.43 (Mar 24) to 16.73, marking an increase of 3.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 26.26. This value is within the healthy range. It has increased from 18.03 (Mar 24) to 26.26, marking an increase of 8.23.
- For Return On Assets (%), as of Mar 25, the value is 13.20. This value is within the healthy range. It has increased from 10.98 (Mar 24) to 13.20, marking an increase of 2.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.00, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.03. It has increased from 0.89 (Mar 24) to 1.03, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.77. This value is within the healthy range. It has decreased from 3.08 (Mar 24) to 2.77, marking a decrease of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 2.39. This value exceeds the healthy maximum of 2. It has decreased from 2.55 (Mar 24) to 2.39, marking a decrease of 0.16.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.62. This value exceeds the healthy maximum of 8. It has increased from 4.38 (Mar 24) to 14.62, marking an increase of 10.24.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 104.15. This value exceeds the healthy maximum of 50. It has decreased from 134.63 (Mar 24) to 104.15, marking a decrease of 30.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 64.93. This value exceeds the healthy maximum of 50. It has decreased from 80.89 (Mar 24) to 64.93, marking a decrease of 15.96.
- For Earning Retention Ratio (%), as of Mar 25, the value is -4.15. This value is below the healthy minimum of 40. It has increased from -34.63 (Mar 24) to -4.15, marking an increase of 30.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 35.07. This value is below the healthy minimum of 40. It has increased from 19.11 (Mar 24) to 35.07, marking an increase of 15.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 67.28. This value is within the healthy range. It has increased from 34.95 (Mar 24) to 67.28, marking an increase of 32.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 31.23. This value is within the healthy range. It has increased from 17.45 (Mar 24) to 31.23, marking an increase of 13.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,550.20. It has increased from 3,118.27 (Mar 24) to 3,550.20, marking an increase of 431.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.17. This value exceeds the healthy maximum of 3. It has decreased from 5.45 (Mar 24) to 5.17, marking a decrease of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 17.30. This value exceeds the healthy maximum of 15. It has decreased from 21.24 (Mar 24) to 17.30, marking a decrease of 3.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 5.24, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is -4.15. This value is below the healthy minimum of 30. It has increased from -34.63 (Mar 24) to -4.15, marking an increase of 30.48.
- For Price / BV (X), as of Mar 25, the value is 6.59. This value exceeds the healthy maximum of 3. It has increased from 5.95 (Mar 24) to 6.59, marking an increase of 0.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 5.24, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Thyrocare Technologies Ltd:
- Net Profit Margin: 13.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 26.26% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.73% (Industry Average ROE: 14.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 31.23
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.39
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 58.3 (Industry average Stock P/E: 78.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | D/37-1, TTC Industrial Area, MIDC, Turbhe, New Mumbai Maharashtra 400703 | compliance@thyrocare.com http://www.thyrocare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rahul Guha | Managing Director & CEO |
| Mr. Dharmil Sheth | Non Executive Director |
| Mr. Hardik Dedhia | Non Executive Director |
| Dr. Dhaval Shah | Non Executive Director |
| Dr.(Mrs.) Indumati Gopinathan | Independent Director |
| Dr.(Ms.) Prapti Gilada | Independent Director |
| Dr. Harshil Vora | Independent Director |
| Mr. Nishant A Shah | Independent Director |
| Mr. Anandh Sundar | Independent Director |
FAQ
What is the intrinsic value of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd's intrinsic value (as of 19 December 2025) is 267.94 which is 38.97% lower the current market price of 439.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 6,999 Cr. market cap, FY2025-2026 high/low of 538/219, reserves of ₹463 Cr, and liabilities of 651 Cr.
What is the Market Cap of Thyrocare Technologies Ltd?
The Market Cap of Thyrocare Technologies Ltd is 6,999 Cr..
What is the current Stock Price of Thyrocare Technologies Ltd as on 19 December 2025?
The current stock price of Thyrocare Technologies Ltd as on 19 December 2025 is 439.
What is the High / Low of Thyrocare Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Thyrocare Technologies Ltd stocks is 538/219.
What is the Stock P/E of Thyrocare Technologies Ltd?
The Stock P/E of Thyrocare Technologies Ltd is 58.3.
What is the Book Value of Thyrocare Technologies Ltd?
The Book Value of Thyrocare Technologies Ltd is 32.5.
What is the Dividend Yield of Thyrocare Technologies Ltd?
The Dividend Yield of Thyrocare Technologies Ltd is 1.59 %.
What is the ROCE of Thyrocare Technologies Ltd?
The ROCE of Thyrocare Technologies Ltd is 26.5 %.
What is the ROE of Thyrocare Technologies Ltd?
The ROE of Thyrocare Technologies Ltd is 17.4 %.
What is the Face Value of Thyrocare Technologies Ltd?
The Face Value of Thyrocare Technologies Ltd is 10.0.